First human test: how does a damaged liver handle new medicine?
NCT ID NCT06813781
Summary
This early-stage study tested how a new drug called AZD5004 is processed by people with different levels of liver damage compared to people with healthy livers. Researchers gave a single dose to 33 adults with mild, moderate, or severe liver impairment, plus a matched healthy group, to measure drug levels and safety. The goal was to understand if and how liver disease changes the way the body handles this medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Lake Forest, California, 92630, United States
-
Research Site
Rialto, California, 92377, United States
-
Research Site
Miami Lakes, Florida, 33014, United States
-
Research Site
Orlando, Florida, 32809, United States
-
Research Site
San Antonio, Texas, 78215, United States
Conditions
Explore the condition pages connected to this study.